If the dollar weakens versus other currencies as inflation moderates, it should boost Teva's sales growth. What happened Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were sliding 5.4% lower as of 11:47 a.m. Teva reported fourth-quarter revenue of $3.88 billion, down 5% year over year.